Novel coronavirus vaccines

Novel coronavirus vaccines

We all have been applying preventive measures to stay away from COVID 19 till date as discussed in our last article also countries like India China using Ayurvedic remedies at home where warm water intake is common but what about those who already are infected from the disease?

Talking about cure, As we all know that there is no proven cure for COVID 19 however controlling its vicious effects doctors researchers are toiling hard day and night for creating some medical cure. We should be well aware of what propositions  and the progress they have reached in the process for some Nobel cause.

Novel Coronavirus vaccines

Chandigarh, April 26 (H): Chandigarh PGI has got a big success in the midst of Corona crisis. PGI has claimed that positive response has been found in the safety trial started as an alternative medicine for corona virus.

PGI has tried Mycovacterium W vaccine, a drug given in the treatment of leprosy, on 6 patients, which has shown positive results. The hospital claims that the patients who needed oxygen during the corona treatment had improved significantly by injecting 0.3 mL of the MW vaccine.

Hospital administration says that the doctors on the patients
Used this drug for three consecutive days and it was found that the use of the vaccine on the patient
Is absolutely safe and positive. Please tell that this drug was also used on patients suffering from leprosy, tuberculosis and pneumonia.
The use of the drug was also found safe in them. Now on the corona patients
The drug has been found safe.

Novel Coronavirus vaccines

Last week, the Government of India sent PGI Chandigarh to Corona
The virus was chosen for the clinical trial of the vaccine. Council of Science &
Industrial research shows corona virus to be used in leprosy
Vaccine Mycovacterium W Clinic
Trial was approved.

The hospital administration told that PGI Chandigarh Government of India
The trust is retained. If it gets approval from the government then the coming
In days, this vaccine will be tried on patients of Corono and also in places. Csi
R. Gujarat-based Pharma Company Cadila Healthcare Limited
Together, the MW vaccine clinical trial on corona virus goes even further
Will stay PGI with Chandigarh in this clinical trial
Delhi AIIMS and Bhopal AIIMS have also been approved.

Novel Coronavirus vaccines

Trial of this drug on corona patients other than PGI Chandigarh
All India Institute of Medical Science (AIIMS) is also being done in Delhi and Bhopal
is. Currently 12 patients of Corona are treated in PGI, Chandigarh.
Its going on.

Various coronavirus vaccines in various stages of development, across the world are:-

Fusogenix DNA vaccine by Entos Pharmaceuticals

Entos Pharmaceuticals is developing Fusogenix DNA vaccine developed by Entos which is working on developing an optimised payload containing multiple protein epitopes derived from SARS-COV-2 proteins, which will stimulate an immune response in the body to prevent COVID-19 infection.

ChAdOx1 nCoV-19 by University of Oxford

The University of Oxford’s ChAdOx1 nCoV-19 is an adenovirus vaccine vector developed by the university’s Jenner Institute. The university is testing the vaccine in a clinical trial planned to be conducted in the Thames Valley Region.

Novel Coronavirus vaccines

Gimsilumab by Roivant Sciences

Roivant Sciences is advancing the development of Gimsilumab a clinical-stage, human monoclonal antibody. The drug targets granulocyte-macrophage colony stimulating factor (GM-CSF), which is a pro-inflammatory cytokine found in high levels in the serum of COVID-19 patients.
Targeting GM-CSF is expected to reduce lung damage and reduce mortality rate in COVID-19 patients.

AdCOVID by Altimmune

Altimmune has collaborated with the University of Alabama at Birmingham (UAB) to develop a single dose intranasal vaccine for COVID-19 named AdCOVID. The company is currently carrying out immunogenicity studies after, which phase one clinical trial material will be developed.
Altimmune and UAB will work with researchers to conduct preclinical animal studies and phase one clinical trial inMI the third quarter of 2020.

TJM2 by I-Mab Biopharma

I-Mab Biopharma is developed TJM2, a neutralising antibody, as a treatment for cytokine storm in patients suffering from a severe case of coronavirus infection. The drug targets the human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is responsible for acute and chronic inflammation.

Coronavirus vaccine by Medicago

Medicago is developing drug candidates against COVID-19 after having produced Virus-Like Particles (VLP) of the coronavirus. The company has formed a collaboration with Laval University’s Infectious Disease Research Centre to develop antibodies against SARS-CoV-2.

Novel Coronavirus vaccines

AT-100 by Airway Therapeutics

Airway Therapeutics is exploring its novel human recombinant protein named AT-100 (rhSP-D) as a treatment for coronavirus. The company has announced a filing with the Respiratory Diseases Branch of the National Institutes of Health to evaluate the drug.
AT-100 has shown efficacy in preclinical studies in reducing inflammation and infection in the lungs, while also generating an immune response against various respiratory diseases.

TZLS-501 by Tiziana Life Sciences

Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6.

Novel Coronavirus vaccines

OYA1 by OyaGen

OyaGen’s OYA1 has shown strong antiviral efficacy against coronavirus in laboratory essays. It was found to be more effective than chlorpromazine HCl in inhibiting SARS-CoV-2 from replicating in cell culture.

Altimmune’s intranasal coronavirus vaccine

An intranasal Covid-19 vaccine is being developed by US-based clinical-stage biopharmaceutical company, Altimmune.

The coronavirus vaccine is being developed based on a vaccine technology platform that is similar to NasoVAX, an influenza vaccine developed by Altimmune.

INO-4800 by Inovio Pharmaceuticals and Beijing Advaccine Biotechnology

Inovio Pharmaceuticals has collaborated with Beijing Advaccine Biotechnology Company to advance the development of the former’s vaccine, INO-4800, as a novel coronavirus vaccine. The company has started pre-clinical testing for clinical product manufacturing.

NP-120 (Ifenprodil) by Algernon Pharmaceuticals

Algernon Pharmaceuticals has announced that it is exploring its NP-120 (Ifenprodil) as a potential treatment COVID-19. Ifenprodil is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist sold under the brand name Cerocal. It has demonstrated efficacy in improving survivability in mice infected with H5N1.

APN01 by University of British Columbia and APEIRON Biologics

A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for COVID-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.

mRNA-1273 vaccine by Moderna and Vaccine Research Center

Moderna and the Vaccine Research Center, a unit of the National Institute of Allergy and Infectious Diseases (NIAID), have collaborated to develop a vaccine for coronavirus. The vaccine targets the Spike (S) protein of the coronavirus.

Let's see whether 100 percent effective proven cure can be discovered and prepared or not we will know in future..